Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Luca Paoluzzi"'
Autor:
Luca Paoluzzi, Thomas J Ow
Publikováno v:
Current Oncology, Vol 28, Iss 1, Pp 574-580 (2021)
Immunotherapies directed at T-cell activation through antibodies targeting checkpoint proteins, such as programmed cell death 1 (PD1), are rapidly becoming the new standard of care in the treatment of several malignancies. Cemiplimab is a monoclonal
Externí odkaz:
https://doaj.org/article/043cf9e05600458682359646e43a72d5
Autor:
Lorenzo Moroni, Doreen Hamann, Luca Paoluzzi, Jeroen Pieper, Joost R de Wijn, Clemens A van Blitterswijk
Publikováno v:
PLoS ONE, Vol 3, Iss 8, p e3032 (2008)
Scaffolds for osteochondral tissue engineering should provide mechanical stability, while offering specific signals for chondral and bone regeneration with a completely interconnected porous network for cell migration, attachment, and proliferation.
Externí odkaz:
https://doaj.org/article/f7dfb63bca50457e8e72eafdc82c3e87
Autor:
Owen A. O'Connor, Michael M. Shen, Jennifer Amengual, Jairo Baquero Buitrago, Enrica Marchi, Matko Kalac, Luca Paoluzzi, Marianna Kruithof-de Julio, Luigi Scotto
PDF file, 43KB.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f8adc69354fbe7b23c5a0e088d004a9
https://doi.org/10.1158/1078-0432.22444259
https://doi.org/10.1158/1078-0432.22444259
Autor:
Owen A. O'Connor, Pier Luigi Zinzani, Jasmine M. Zain, Venkatraman E. Seshan, Luigi Scotto, Luca Paoluzzi, Enrica Marchi
Purpose: Pralatrexate (10-propargyl-10-deazaaminopterin) is an antifolate with improved cellular uptake and retention due to greater affinity for the reduced folate carrier (RFC-1) and folyl-polyglutamyl synthase. Based on the PROPEL data, pralatrexa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b83988d4f8c06d2496f6985339cdb10
https://doi.org/10.1158/1078-0432.c.6519545.v1
https://doi.org/10.1158/1078-0432.c.6519545.v1
Autor:
Owen A. O'Connor, Michael M. Shen, Jennifer Amengual, Jairo Baquero Buitrago, Enrica Marchi, Matko Kalac, Luca Paoluzzi, Marianna Kruithof-de Julio, Luigi Scotto
Purpose: To generate a transgenic mouse that when crossed with spontaneous mouse models of lymphoma will allow for quantitative in vivo measurement of tumor burden over the entire spectrum of the disease and or response to therapy in a “disease”
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10673136c72fc10ff8ce480fad098332
https://doi.org/10.1158/1078-0432.c.6520121.v1
https://doi.org/10.1158/1078-0432.c.6520121.v1
Autor:
Owen A. O'Connor, Michael M. Shen, Jennifer Amengual, Jairo Baquero Buitrago, Enrica Marchi, Matko Kalac, Luca Paoluzzi, Marianna Kruithof-de Julio, Luigi Scotto
PDF file, 576KB, Confocal analysis of PBMC of A) wild type and B) single transgenic mice. Mature naive B cells expressing the cherry protein were observed in freshly isolated PBMC stained with a, c, e and g) DAPI, to visualize nuclei. b, d, f and h)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27548a5a57184dad63df379531e5f05f
https://doi.org/10.1158/1078-0432.22444262
https://doi.org/10.1158/1078-0432.22444262
Autor:
Owen A. O'Connor, Pier Luigi Zinzani, Jasmine M. Zain, Venkatraman E. Seshan, Luigi Scotto, Luca Paoluzzi, Enrica Marchi
Supplementary Data from Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in In vitro and In vivo Models of T-Cell Lymphoid Malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01597d6612472360278e27497e8f717c
https://doi.org/10.1158/1078-0432.22442924
https://doi.org/10.1158/1078-0432.22442924
Autor:
Owen A. O'Connor, Venkatraman E. Seshan, Jasmine Zain, Enrica Marchi, Luigi Scotto, Luca Paoluzzi
Supplementary Data from Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e76fe410c4fc0e56e5910a2b6512fcb1
https://doi.org/10.1158/1078-0432.22440399.v1
https://doi.org/10.1158/1078-0432.22440399.v1
Autor:
Emanuela Palmerini, Marco Gambarotti, Antoine Italiano, Michael J. Nathenson, Ravin Ratan, Palma Dileo, Salvatore Provenzano, Robin L. Jones, Steven G. DuBois, Javier Martin-Broto, Enrique de Alava, Giacomo G. Baldi, Giovanni Grignani, Virginia Ferraresi, Antonella Brunello, Luca Paoluzzi, Rossella Bertulli, Nadia Hindi, Michael Montemurro, Christian Rothermundt, Stefania Cocchi, Carmen Salguero-Aranda, Davide Donati, Juan D. Martin, Amr H. Abdelhamid Ahmed, Alessandro Mazzocca, Elisa Carretta, Marilena Cesari, Michela Pierini, Alberto Righi, Marta Sbaraglia, Maria A. Laginestra, Katia Scotlandi, Angelo P. Dei Tos, Toni Ibrahim, Silvia Stacchiotti, Bruno Vincenzi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::242da8bd8faf27427a95457f98a80c67
https://hdl.handle.net/11577/3468778
https://hdl.handle.net/11577/3468778
Autor:
Thomas J. Ow, Luca Paoluzzi
Publikováno v:
Current Oncology
Current Oncology, Vol 28, Iss 57, Pp 574-580 (2021)
Current Oncology, Vol 28, Iss 57, Pp 574-580 (2021)
Immunotherapies directed at T-cell activation through antibodies targeting checkpoint proteins, such as programmed cell death 1 (PD1), are rapidly becoming the new standard of care in the treatment of several malignancies. Cemiplimab is a monoclonal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2a879b9c401a46db27bb2bff12f5b5e
http://europepmc.org/articles/PMC7903284
http://europepmc.org/articles/PMC7903284